In Situ Validation of VEGFR-2 and Α v SS 3 Integrin as Targets for Breast Lesion Characterization

Angiogenesis - Netherlands
doi 10.1007/s10456-016-9499-4
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Erratum To: In Situ Validation of VEGFR-2 and Α v SS 3 Integrin as Targets for Breast Lesion Characterization

Angiogenesis
Cancer ResearchClinical BiochemistryPhysiology
2016English

Integrin Α-3 SS-1’s Central Role in Breast Cancer, Melanoma and Glioblastoma Cell Aggregation Revealed by Antibodies With Blocking Activity

mAbs
AllergyImmunology
2019English

Combined Blockade of VEGFR-2 and VEGFR-3 Inhibits Inflammatory Lymphangiogenesis in Early and Middle Stages

Investigative Ophthalmology and Visual Science
Molecular NeuroscienceOphthalmologySensory SystemsCellular
2011English

Validation of the P21-Activated Kinases as Targets for Inhibition in Neurofibromatosis Type 2

Cancer Research
Cancer ResearchOncology
2008English

Generation and Characterization of a Human Nanobody Against VEGFR-2

Acta Pharmacologica Sinica
MedicinePharmacology
2016English

The Role of the Α v Β 3 Integrin in Lamina Cribrosa Cells and the Possible Role in Glaucoma Pathogenesis

Acta Ophthalmologica
MedicineOphthalmology
2018English

Integrin Β3 Crosstalk With VEGFR Accommodating Tyrosine Phosphorylation as a Regulatory Switch

PLoS ONE
Multidisciplinary
2012English

In Situ Characterization of Projectile Penetration Into Sand Targets

2017English

Nanotetrac Targets Integrin Αvβ3 on Tumor Cells to Disorder Cell Defense Pathways and Block Angiogenesis

OncoTargets and Therapy
OncologyPharmacology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy